BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/22/2021 9:56:10 AM | Browse: 449 | Download: 748
 |
Received |
|
2021-02-26 11:02 |
|
Peer-Review Started |
|
2021-02-26 11:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-07 01:33 |
|
Revised |
|
2021-06-14 11:40 |
|
Second Decision |
|
2021-09-02 02:54 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-09-02 05:43 |
|
Articles in Press |
|
2021-09-02 05:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-10-19 04:57 |
|
Publish the Manuscript Online |
|
2021-10-22 09:56 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ayumi Saito, Hiroshi Yoshida, Tadaaki Nishikawa and Kan Yonemori |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hiroshi Yoshida, MD, PhD, Staff Physician, Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 1040045, Japan. hiroyosh@ncc.go.jp |
| Key Words |
Endometrial cancer; Serous carcinoma; Carcinosarcoma; Human epidermal growth factor receptor 2; Chemotherapy; Antibody-drug conjugates |
| Core Tip |
Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. A significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer, including serous carcinoma and carcinosarcoma, shows a dismal prognosis. Recent molecular analyses revealed human epidermal growth factor receptor 2 (HER2) overexpression/gene amplification in 20%-40% of patients with type II endometrial cancer. Notably, HER2 targeted therapy for type II endometrial cancer has been dramatically developed. We review the recent findings on endometrial cancer, current treatment, optimized HER2 testing, key clinical trials on HER2 targeted therapy, and future directions in these aggressive endometrial cancers. |
| Publish Date |
2021-10-22 09:56 |
| Citation |
Saito A, Yoshida H, Nishikawa T, Yonemori K. Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: clinical and pathological perspectives. World J Clin Oncol 2021; 12(10): 868-881 |
| URL |
https://www.wjgnet.com/2218-4333/full/v12/i10/868.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v12.i10.868 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
